Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

Inclusion Criteria * Male or non-pregnant female at least 18 years of age at time of consent * One or both eyes having a history of recurrent non-infectious uveitis affecting the posterior segment of the eye with or without anterior uveitis \> 1 year duration. * During the 12 months prior to enrollment (Day 1), the study eye has either received treatment: * systemic corticosteroid or other systemic therapies given for at least 3 months, and/or * at least 2 intra- or peri-ocular injections of corticosteroid for management of uveitis OR the study eye has experienced recurrence: * at least 2 separate recurrences of uveitis requiring systemic, intra- or peri-ocular injection of corticosteroid * At the time of enrollment (Day 1), study eye has \< 10 anterior chamber cells/HPF and a vitreous haze ≤ grade 2. * Visual acuity of study eye is at least 15 letters on the ETDRS chart * Subject is not planning to undergo elective ocular surgery during the study * Subject has ability to understand and sign the Informed Consent Form * Subject is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures Exclusion Criteria * Allergy to fluocinolone acetonide or any component of the FAI insert * History of posterior uveitis only that is not accompanied by vitritis or macular edema * History of iritis only and no vitreous cells, anterior chamber cells or vitreous haze * Uveitis with infectious etiology * Vitreous hemorrhage * Intraocular …